Endocrinology, Vol 125, 2945-2949, Copyright © 1989 by Endocrine Society

ARTICLES

Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist

I Gozes, E Meltzer, S Rubinrout, DE Brenneman and M Fridkin
Department of Hormone Research, Weizmann Institute of Science, Rehovot, Israel.

Vasoactive intestinal peptide (VIP) has been suggested as a neurotransmitter mediating penile erection. We now show that VIP can stimulate sexual behavior in rats with reduced masculine potential due to pituitary grafting or castration. This effect was attenuated in the presence of a novel VIP antagonist, devised by a hybrid peptide strategy. Thus, we have synthesized a molecule combining a portion of VIP with a portion of neurotensin, peptides of opposite pharmacological action on cAMP formation and smooth muscle relaxation. The hybrid peptide markedly inhibited VIP's effect on sexual behavior. This inhibition was manifested by a significant increase in the mean interval between copulatory events (greater than 3-fold change) coupled with a blockade of VIP-stimulated ejaculation. Other putative VIP antagonists were not as effective in blocking these activities. Thus, our results imply that VIP is not only associated with penile erection, but is involved in sexual behavior as well. Furthermore, the hybrid antagonist was shown to inhibit VIP binding in glial cell cultures. The availability of highly potent VIP antagonists may offer a route to study the possible multiple VIP receptors as well as help delineate other biological activities attributable to VIP.

This article has been cited by other articles:

				D. L. Sigalet, L. E. Wallace, J. J. Holst, G. R. Martin, T. Kaji, H. Tanaka, and K. A. Sharkey Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2 Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G211 - G221. [Abstract] [Full Text] [PDF]

				Y. Fukushima, H. Hikichi, K. Mizukami, T. Nagayama, M. Yoshida, M. Suzuki-Kusaba, H. Hisa, T. Kimura, and S. Satoh Role of endogenous PACAP in catecholamine secretion from the rat adrenal gland Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1562 - R1567. [Abstract] [Full Text] [PDF]

				S. J. Servoss, S. J. Lee, G. Gibney, I. Gozes, D. E. Brenneman, and J. M. Hill IGF-I as a Mediator of VIP/Activity-Dependent Neurotrophic Factor-Stimulated Embryonic Growth Endocrinology, August 1, 2001; 142(8): 3348 - 3353. [Abstract] [Full Text] [PDF]

				J. W. Tams, R. M. Jørgensen, A. Holm, and J. Fahrenkrug Creation of a Selective Antagonist and Agonist of the Rat VPAC1 Receptor Using a Combinatorial Approach with Vasoactive Intestinal Peptide 6-23 as Template Mol. Pharmacol., November 1, 2000; 58(5): 1035 - 1041. [Abstract] [Full Text]

				R. Busto, I. Carrero, L. G. Guijarro, R. M. Solano, J. Zapatero, F. Noguerales, and J. C. Prieto Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung Am J Physiol Lung Cell Mol Physiol, July 1, 1999; 277(1): L42 - L48. [Abstract] [Full Text] [PDF]

				I. GOZES, O. PERL, R. ZAMOSTIANO, S. RUBINRAUT, M. FRIDKIN, L. SHOCHAT, and L. M. LEWIN Multiple Actions of a Hybrid PACAP Antagonist: Neuronal Cell Killing and Inhibition of Sperm Motility Ann. N.Y. Acad. Sci., December 11, 1998; 865(1): 266 - 273. [Abstract] [Full Text] [PDF]

				A. J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al. International Union of Pharmacology. XVIII. Nomenclature of Receptors for Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Pharmacol. Rev., June 1, 1998; 50(2): 265 - 270. [Abstract] [Full Text] [PDF]